Emerging diagnostic and treatment approaches in organ and stem cell transplantation
Lead Research Organisation:
King's College London
Department Name: Medicine School Office
Abstract
Replacement of diseased organs and cells by healthy tissue is a dream that has partly been realised through progress in transplantation over the last 50 years. However, for transplantation therapy to achieve greater success and on a wider scale, advance is needed in several directions. These include finding supplementary sources of donor tissues and cells that lend themselves for therapy of a larger number of conditions, such as kidney and liver failure, arthritis, diabetes and tooth loss; and a way of ensuring acceptance of the replacement tissue without the need for lifelong drugs that block the immune system. To accelerate progress, experts in basic biology and transplant medicine at King s College London plan to come together in a joint venture with the Medical Research Council, to form the UK s first MRC Centre for Translation of Research in Transplantation. The Centre s mission is to put research in transplantation on a new trajectory to deliver more rapid and effective modes of diagnosis and treatment. The programme of research will apply extensive knowledge of human immunology, stem cell biology, genomics and imaging to develop new areas that will benefit human health. In collaboration with the King s College Centre of Medical Law and Ethics, the MRC Centre will also play a pivotal role in training and education.
Technical Summary
The immune system represents a formidable barrier to organ and cell transplantation adding to the problems caused by severe shortage of replacement tissues. We present a co-ordinated and integrated vision for how basic and clinical research can combine at a single centre to provide new diagnostic and therapeutic opportunities that can be applied to the alleviation of human suffering. The premise is that more specific manipulation of the inflammatory and immune systems will increase the number of donor organs that can be used for transplantation, will reduce the number of mid-term graft failures and will lead to minimisation or elimination of pan-immunosuppressive therapies, thus lowering the incidence of related malignancies. The proposed strategies include: (1) development and clinical trial of membrane targeted regulators of the complement and clotting cascades for the pre-treatment of donor organs; (2) investigation and development of clinical-grade cell based therapies to promote long-term graft acceptance without continuous immunosuppressive drugs; (3) development of new imaging methods for visualising and monitoring the activity of innate and adaptive immune systems, initially in pre-clinical models; (4) clinical and experimental evaluation of biomarkers that help to predict and interpret outcomes of transplantation; and (5) strategies for addressing the impact of the immune response in allogeneic stem cell based therapies. Outcome measures will take into account the rates of organ dysfunction due to ischaemia-reperfusion insult and acute rejection crises, annual graft survival rates, indices of chronic rejection, infection rates, clinical tools for measurement of tolerance, specificity and sensitivity of imaging procedures and predictive analysis in large, well-defined patient cohorts. The initial application and exploitation of the research results will take place in the fields of liver, kidney, bone marrow and stem cell-based repair/replacement of tooth and articular cartilage, and later will extend to other organs and tissues. The programme of studies within the Centre will provide a vibrant cross-disciplinary environment in which future leaders of research will acquire essential skills including the confidence to engage public interest in transplantation research and its benefits for patients.
Organisations
- King's College London, United Kingdom (Collaboration, Lead Research Organisation)
- University of Oxford, United Kingdom (Collaboration)
- University of Southampton, United Kingdom (Collaboration)
- University College London, United Kingdom (Collaboration)
- University of Edinburgh, United Kingdom (Collaboration)
- University of Warwick, United Kingdom (Collaboration)
- AdProTec (Collaboration)
- University of Bristol, United Kingdom (Collaboration)
- University of Bath, Bath (Collaboration)
- Imperial College London, United Kingdom (Collaboration)
- The Wellcome Trust Sanger Institute (Collaboration)
- Newcastle University, United Kingdom (Collaboration)
- Yale University (Collaboration)
- Great North Children's Hospital (GNCH) (Collaboration)
- University of East Anglia, United Kingdom (Collaboration)
- Medical Research Council (Collaboration)
- Harvard University (Collaboration)
- University of Cambridge (Collaboration)
- Cardiff University, United Kingdom (Collaboration)
- Manchester University NHS Foundation Trust, Manchester (Collaboration)
- Alexion Pharmaceuticals (Collaboration)
- Leeds Teaching Hospitals NHS Trust, United Kingdom (Collaboration)
- University of Pittsburgh (Collaboration)
- University of Leicester, United Kingdom (Collaboration)
Publications

Abboudi H
(2013)
Current status of validation for robotic surgery simulators - a systematic review.
in BJU international

Abboudi H
(2012)
Decision making in urological surgery.
in International urology and nephrology

Ahmed K
(2011)
How to develop a simulation programme in urology.
in BJU international

Ahmed K
(2012)
Assessing the cost effectiveness of robotics in urological surgery - a systematic review.
in BJU international

Bacchetta R
(2014)
Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells.
in Frontiers in immunology

Bartel G
(2013)
Donor specific transplant tolerance is dependent on complement receptors.
in Transplant international : official journal of the European Society for Organ Transplantation

Challacombe B
(2012)
Focal HIFU for prostate cancer.
in The Lancet. Oncology

Challacombe B
(2011)
Recognizing and managing the complications of prostate biopsy.
in BJU international

Chen D
(2013)
Enhanced effect of inhibition of thrombin on endothelium in murine endotoxaemia: specific inhibition of thrombocytopenia.
in Thrombosis research

Choudhury SM
(2011)
Oncological outcomes of robot-assisted radical cystectomy.
in BJU international
Description | British Transplantation Society Living Donor Transplantation Guidelines |
Geographic Reach | National |
Policy Influence Type | Membership of a guideline committee |
Description | MRC Centre for Transplantation Consultation Response to Academy of Medical Sciences Call for Evidence: Review of the Regulation and Governance of Medical Research |
Geographic Reach | National |
Policy Influence Type | Membership of a guideline committee |
Impact | Expected to influence Goverment policy on: having a "single research regulator" with combined responsibility for different aspects of research regulation; the future of the National Research Ethics Service; and the reorganisation of the research regulatory activities of the Human Tissue Authority (which is directly relevant to transplantation). |
Description | MRC Centre for Transplantation Response to Nuffield Council on Bioethics Consultation paper Giver and Take? Human Bodies in Medicine and Research |
Geographic Reach | National |
Policy Influence Type | Membership of a guideline committee |
Description | Organ Donation Taskforce Ethics Working Group |
Geographic Reach | National |
Policy Influence Type | Membership of a guideline committee |
Description | Technology Strategy Board Assessor Briefing for Healthcare |
Geographic Reach | National |
Policy Influence Type | Participation in advisory committee |
Description | British Transplant Society Fellowship Award |
Amount | £40,000 (GBP) |
Organisation | British Transplantation Society (BTS) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2008 |
End | 10/2009 |
Description | Guy's & St Thomas' Charity - New Services and Innovations Grant |
Amount | £20,000 (GBP) |
Organisation | Guy’s & St Thomas’ Charity |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 06/2010 |
End | 01/2011 |
Description | MRC Centenary Event award |
Amount | £30,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2012 |
End | 06/2013 |
Description | MRC Centenary award |
Amount | £45,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 06/2012 |
End | 05/2013 |
Description | MRC Centre Grant |
Amount | £2,700,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2007 |
End | 09/2012 |
Description | MRC Centre Grant (Directors Initiative) |
Amount | £250,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 10/2007 |
End | 09/2012 |
Description | MRC Developmental Clinical Study |
Amount | £1,727,417 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 08/2011 |
End | 06/2014 |
Description | MRC Director's Initiative |
Amount | £203,088 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2007 |
End | 08/2012 |
Description | MRC PhD Studentship |
Amount | £50,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 10/2007 |
End | 09/2010 |
Description | MRC Project Grant |
Amount | £600,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 10/2008 |
End | 09/2011 |
Description | MRC Project Grant |
Amount | £520,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 12/2007 |
End | 12/2010 |
Description | MRC Public Engagement Grant |
Amount | £10,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 08/2010 |
End | 10/2010 |
Description | NIHR Biomedical Center Grant |
Amount | £5,369,000 (GBP) |
Organisation | National Institute for Health Research |
Department | NIHR Comprehensive Biomedical Research Centre, Guy's and St Thomas |
Sector | Public |
Country | United Kingdom |
Start | 04/2007 |
End | 03/2012 |
Description | NIHR Senior Investigator award |
Amount | £40,000 (GBP) |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 05/2008 |
End | 04/2012 |
Description | Public Engagement |
Amount | £10,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 08/2010 |
End | 01/2011 |
Description | Wellcome Trust Equipment Grant |
Amount | £977,000 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2007 |
End | 08/2010 |
Description | Wellcome Trust Project Grant |
Amount | £222,000 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2006 |
End | 01/2009 |
Title | Complement imaging technology |
Description | Cloning of complement receptor 2 and modification to develop a new imaging tool for detection of complement activation by external body imaging. |
Type Of Material | Technology assay or reagent |
Year Produced | 2011 |
Provided To Others? | Yes |
Impact | Imaging ligand adapted for potential clinical studies |
Title | Complement imaging technology |
Description | Cloning of complement receptor 2 and modification to develop a new imaging tool for detection of complement activation by external body imaging. |
Type Of Material | Technology assay or reagent |
Year Produced | 2015 |
Provided To Others? | No |
Impact | Being developed for clinical investigation |
Title | Core administrative and laboratory facilities |
Description | 1.Refurbishment of office and laboratory space including new human protein therapeutics laboratory to accommodate Centre activities, including new activities. 2.New administrative/research structure for the MRC Centre including Centre Manager, administrative assistant, statistical support and microsurgical team. |
Type Of Material | Improvements to research infrastructure |
Year Produced | 2007 |
Provided To Others? | Yes |
Impact | 1.Facilitated several major grant awards, as listed. 2.Developed a dedicated Centre website with strongly positive feedback 3.Increased media profile, as listed 4.Dissemination through workshops and meetings as listed and selection for the British Science Festival 2010. |
Title | Quantitative PCR |
Description | Through the Centre collaboration with Genetics, we have established rigorous quantitative expression methods on transplant samples in liver and kidney recipients. |
Type Of Material | Technology assay or reagent |
Year Produced | 2008 |
Provided To Others? | No |
Impact | Work in progress |
Description | AdProTec, UK |
Organisation | AdProTec |
Country | United Kingdom |
Sector | Private |
PI Contribution | 1.Established the rationale of membrane targetting approach to prevent complement injury in donor kidney organs. 2. Enabled pre clinical study in prevention of reperfusion damage. 3. Enabled and led clinical (phase IIa) study to determine safety and feasibility of treating donor organs prior to transplantation. |
Collaborator Contribution | The company provided chemicals and consumables for this study |
Impact | Publications - Pubmed references 14507653 and 16510763 Joint patent application (Case 40336). This is now wholly owned by King's College London. Led to development of PhD project successfully awarded in 2006. Keynote symposium presentations including Presidents Lecture, Transplantation Society for Australia and New Zealand 2007. |
Description | Alexion Pharmaceuticals |
Organisation | Alexion Pharmaceuticals |
Country | United States |
Sector | Private |
PI Contribution | We collaborated on an investigator led pre clinical study to determine the impact of complement inhibitor (anti-C5) on reperfusion injury in native and transplant kidneys. |
Collaborator Contribution | Alexion Pharmaveuticals provided Chemicals, Consumables and animals to this study |
Impact | The therapeutic antibody failed to penetrate into transplanted kidney and therefore helped to define types of injury that would not amenable to this particular therapeutic strategy. |
Description | Complement UK |
Organisation | Cardiff University |
Department | Infection and Immunity |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Complement UK |
Organisation | Great North Children's Hospital (GNCH) |
Department | Pediatric Nephrology |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Complement UK |
Organisation | Imperial College London |
Department | Faculty of Medicine |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Complement UK |
Organisation | Leeds Teaching Hospitals NHS Trust |
Department | Department of Clinical Haematology |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Complement UK |
Organisation | Manchester University NHS Foundation Trust |
Department | Nephrology and Transplantation |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Complement UK |
Organisation | Medical Research Council (MRC) |
Department | MRC Human Genetics Unit |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Complement UK |
Organisation | Newcastle University |
Department | Institute of Cellular Medicine |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Complement UK |
Organisation | Newcastle University |
Department | Institute of Human Genetics |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Complement UK |
Organisation | University College London |
Department | Institute of Neurology |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Complement UK |
Organisation | University College London |
Department | Institute of Ophthalmology UCL |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Complement UK |
Organisation | University College London |
Department | Research Department of Epidemiology and Public Health |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Complement UK |
Organisation | University College London |
Department | Structural Molecular Biology |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Complement UK |
Organisation | University of Bath |
Department | Department of Biology and Biochemistry |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Complement UK |
Organisation | University of Bristol |
Department | School of Cellular and Molecular Medicine |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Complement UK |
Organisation | University of Cambridge |
Department | Department of Clinical Biochemistry |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Complement UK |
Organisation | University of Cambridge |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Complement UK |
Organisation | University of East Anglia |
Department | School of Medicine UEA |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Complement UK |
Organisation | University of Edinburgh |
Department | School of Biological Sciences |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Complement UK |
Organisation | University of Edinburgh |
Department | School of Chemistry |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Complement UK |
Organisation | University of Leicester |
Department | Department of Infection, Immunity and Inflammation |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Complement UK |
Organisation | University of Leicester |
Department | Department of Molecular and Cell Biology |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Complement UK |
Organisation | University of Oxford |
Department | Sir William Dunn School of Pathology |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Complement UK |
Organisation | University of Southampton |
Department | School of Medicine Southampton |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Complement UK |
Organisation | University of Warwick |
Department | Warwick Medical School |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy. |
Collaborator Contribution | The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding. |
Impact | Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep) |
Start Year | 2009 |
Description | Harvard University |
Organisation | Harvard University |
Department | Harvard Medical School |
Country | United States |
Sector | Academic/University |
PI Contribution | We have built a research collaboration on biomarkers in transplantation with Professor Terry Strom, by giving him access to patients and testing his samples in the kidney transplant unit. We have jointly written grant awards (L. Barber and S. Longi) and we have jointly funded a joint postdoctoral researcher to look at tissue stress factors in transplantation. In addition, we have set up teaching sessions to introduce research opportunities from Harvard University and we have set up a major international symposium (GMEC Genetics Symposium, November 2009) which featured his work. |
Collaborator Contribution | We have access to confidential information and primer sequences that define potential biomarkers currently under investigation in our Centre as a result. It has facilitated recruitment of a new Professor to the MRC Centre from the USA. |
Impact | 1. Organising GMEC Genetics Symposium (2009) 2. Organising workshops 3. Putting in two grant applications 4. Partnership with Quest (negotiation stage) |
Start Year | 2007 |
Description | Lombardi-Mullen |
Organisation | King's College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | regulatory T cell expertise and models of skin transplantation |
Collaborator Contribution | expertise in full body imaging |
Impact | 2 publications already in pub med and 3 more in preparation |
Start Year | 2008 |
Description | Lombardi-Nestle |
Organisation | King's College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | regulatory T cell expertise and knowledge in the mechanisms of tolerance |
Collaborator Contribution | establishing in vivo model of human skin transplantation |
Impact | See publications - PubMed ID 22937164 & J.Exp.Med.209(5) 935-945; Ali et al. Plos ONE (In Press) |
Start Year | 2008 |
Description | Requirement of complement C3 for transplant tolerance induction |
Organisation | King's College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Led to the initial observation that C3 deficient mice were resistant to tolerance induction. |
Collaborator Contribution | Provided a Clinical Fellow with an interest in complement and transplantation. This has enabled a new scientific question to be addressed. |
Impact | The initial results showing the requirement for C3 in tolerance to skin grafts was presented at an international meeting. |
Start Year | 2008 |
Description | University of Pittsburgh - Immunology Department |
Organisation | University of Pittsburgh |
Department | Department of Pharmaceutical Sciences |
Country | United States |
Sector | Academic/University |
PI Contribution | We provided the expertise, laboratory equipment and facilities and intellectual input into this project. The work was partly funded by NIH grant. |
Collaborator Contribution | Contributed one year of work in our laboratory for a self funded PhD student. |
Impact | 1. Imperial College PhD award for Chih Che Li 2. Publications: a. Pubmed ID: 19000927 b. Pubmed ID: 18791452 |
Start Year | 2007 |
Description | Wellcome Trust Case Control Consortium 3 |
Organisation | The Wellcome Trust Sanger Institute |
Country | United Kingdom |
Sector | Charity/Non Profit |
PI Contribution | Graham Lord and co-applicants in the MRC Centre put together a transplant GWAS proposal, which led to a network of 22 transplant centres in the UK and Ireland who will contribute donor and recipient DNA. |
Collaborator Contribution | funding and SNP analysis |
Impact | A pilot genome study involving around 600 donor-recipient pairs at Guy's Hospital has been completed. Publication on Complement genes submitted. |
Start Year | 2009 |
Description | Yale University |
Organisation | Yale University |
Country | United States |
Sector | Academic/University |
PI Contribution | Development of collaborative research programme |
Collaborator Contribution | Development of collaborative programme |
Impact | Publication available in e Print. Author Prof Adrian Hayday. Journal of Investigative Dermatology 2009. Study of T cells that promote tissue growth and wound repair. |
Start Year | 2007 |
Title | Anticomplement Compounds |
Description | Recovery of IP and materials related to membrane-localising ("cytotopic") technology discovered by our lead protein chemist and head of Protein Therapeutics Laboratory (before joining our Centre). |
IP Reference | US7888318 |
Protection | Patent granted |
Year Protection Granted | 2011 |
Licensed | Commercial In Confidence |
Impact | Return of the IP will enable new grant proposals and the conduct of a Phase IIB efficacy study in transplant patients. |
Title | Antithrombotic Compounds |
Description | It has been found that linkage of anticoagulant peptides to membrane-localising ("cytotopic") reagents generates conjugates which are capable of inhibiting thrombin when attached to cell surfaces. This enables organs to be anticoagulated by perfusion ex-vivo prior to transplantation into the recipient. For the first time, it appears to be possible to separate local antithrombotic effects from systemic pharmacological ones using a readily translatable therapeutic agent. |
IP Reference | WO2011027175 |
Protection | Patent granted |
Year Protection Granted | 2011 |
Licensed | No |
Impact | It may be possible to control thrombosis in transplantation (for example, in pancreatic and islet cell transplantation and in the prevention of antibody-mediated acute rejection) using this approach, as shown in early pre-clinical models in rat. |
Title | Antithrombotic agent (PTL004) |
Description | It has been found that linkage of anticoagulant peptides to membrane-localising ("cytotopic") reagents generates conjugates which are capable of inhibiting thrombin when attached to cell surfaces. This enables organs to be anticoagulated by perfusion ex-vivo prior to transplantation into the recipient. For the first time, it appears to be possible to separate local antithrombotic effects from systemic pharmacological ones using a readily translatable therapeutic agent. It may be possible to control thrombosis in transplantation (for example, in pancreatic and islet cell transplantation and in the prevention of antibody-mediated acute rejection) using this approach. |
Type | Therapeutic Intervention - Drug |
Current Stage Of Development | Initial development |
Year Development Stage Completed | 2009 |
Development Status | Under active development/distribution |
Impact | First product of its kind enabling prevention of Thrombosis in an organ transplant without having to anti-coagulate the recipient. Potential use in organs transplanted into pre-sensitised recipients. |
Title | Cytotopic human interleukin 15 |
Description | Modified human cytokine designed to generate regioselective immune stimulation within human tumours. Principle source of funding: Prostate Cancer UK/Heathside Fund |
Type | Therapeutic Intervention - Drug |
Current Stage Of Development | Initial development |
Year Development Stage Completed | 2012 |
Development Status | Under active development/distribution |
Impact | N/A |
Title | Empirikal-Mirococept |
Description | Membrane - interactive complement inhibitor used by ex vivo perfusion into isolated organ. About to enter definitive Phase II study. Drug manufacture completed to accepted standard. MHRA approved. Patient recruitment imminent. Souce of funding: MRC DCS grant. Recruitment began in July 2015 and 19 patients are now undergoing treatment. |
Type | Therapeutic Intervention - Drug |
Current Stage Of Development | Early clinical assessment |
Year Development Stage Completed | 2006 |
Development Status | Under active development/distribution |
Clinical Trial? | Yes |
Impact | Validation of the membrane-binding (cytotopic) approach used in Mirococept and the consequent development of this technology as a platform. Large scale manufacture and quality assessment for clinical trial completed. Completed investigators brochure. Ethics approved. MHRA approved. Patient recruitment open. |
URL | http://www.mykidney.org/Research/ResearchAtGuys.aspx |
Title | Membrane targeted anti-thrombin PTL006 |
Description | A membrane targeted anti-coagulant for intented use in donor kidneys transplanted into high risk (highly sensitised) recipients. Currently at proof-of-principle stage in rat model. Current funding - MRC Centre Grant Directors Initiative. |
Type | Therapeutic Intervention - Drug |
Current Stage Of Development | Refinement. Non-clinical |
Year Development Stage Completed | 2010 |
Development Status | Under active development/distribution |
Impact | Patent application registered. |
Description | Associate Parliamentary Committee for Surgical Services |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | Yes |
Geographic Reach | National |
Primary Audience | Policymakers/politicians |
Results and Impact | Advised House of Lords on the need for simulation for patient safety, European Working Time Directive, Emergency Surgery Awaiting outcomes |
Year(s) Of Engagement Activity | 2012 |
Description | Away Day |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | Over 70 delegates from across the Centre and beyond enjoyed a full programme of events including presentations from Dr Varuna Aluvihare and Professor Steven Sacks; a series of talks on current areas of clinical translational research and a lively debate on some of the major issues facing the Centre. Issues discussed included defining priority areas for clinical/academic research and the Centre's promotion of clinical engagement. Professor Andrew Bradley from Cambridge University delivered some provocative insights in his keynote speech, outlining possible future challenges to the Centre. That the away day attracted such a diverse audience only added to its success. Some excellent ideas emerged at the event, such as developing supported mentorship for staff and creating opportunities for clinicians to shadow lab staff and vice versa. Also suggested was a Centre discussion board for staff from all areas to share ideas in an easy to use forum. |
Year(s) Of Engagement Activity | 2009 |
Description | Away Day |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Primary Audience | Participants in your research and patient groups |
Results and Impact | A meeting to engage clinicians in the scientific programme of the Centre and vice versa, and to promote patient-involvement in the Centre's mission, through breakout sessions, some of which were patient-led. A collaborative grant proposal has been submitted to the NIHR; progress with Transplant Biobank across the Centre; KPA involvement in the planning of the Bristish Science Festival; increased coverage in KPA newsletters; started monthly educational sessions with patients. |
Year(s) Of Engagement Activity | 2010 |
Description | BBC R4 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | Recorded broadcast on national radio on the ethics of transplantation as part of the BBCR4 science series Inside the Ethics Committee |
Year(s) Of Engagement Activity | 2012 |
Description | BBC Radio 4 Interview |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Primary Audience | Public/other audiences |
Results and Impact | Prof Steven Sacks describes his work on finding an easier way to get the body to accept a new organ on BBC Radio 4. Publicity for the MRC Centre for Transplantation. |
Year(s) Of Engagement Activity | 2008 |
Description | BBC Radio 4 Interview |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Primary Audience | Public/other audiences |
Results and Impact | Prof Steven Sacks describes his work on finding an easier way to get the body to accept a new organ on BBC Radio 4. Publicity for the work of the MRC Centre for Transplantation. |
Year(s) Of Engagement Activity | 2008 |
Description | BBC Radio 4 Interview |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Primary Audience | Public/other audiences |
Results and Impact | BBC Radio 4 invited Professor Steven Sacks to talk about a new technique that would extend the life of a kidney transplant significantly. The story received media attention and was later supported by the successful application of an award to help with first in man clinical trials. |
Year(s) Of Engagement Activity | 2010 |
Description | BBC Radio 4 interview |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Primary Audience | Public/other audiences |
Results and Impact | Prof Steven Sacks describes his work on finding an easier way to get the body to accept a new organ at the MRC Centre for Transplantation, on BBC Radio 4. Gain exposure of the MRC Centre for Transplantation. |
Year(s) Of Engagement Activity | 2008 |
Description | Ethics Symposium |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | The MRC Centre for Transplantation held an ethics workshop entitled 'on the possibility of translation'. The workshop was attended by ethicists, lawyers, scientists, social scientists and clinicians. At the end of the meeting the group made two proposals. First, that a one day seminar be held to address the problem of nomenclature and regulatory processes in the context of translational research. Second, that a Health Services Research Fellow (a post doctoral social scientist) be appointed to address generally how innovative research methods are conceived by patients, clinicians, scientific researchers, and organ donors, and to address more specifically issues relating to biomarker studies and clinical transplantation. This appointment is now underway. |
Year(s) Of Engagement Activity | 2009 |
Description | Extending the Life of the Transplant |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | Yes |
Primary Audience | Public/other audiences |
Results and Impact | The meeting will bring members of the public face to face with researchers, clinicians and patients dealing with the early failure of transplants and discuss how scientific advance is envisaged to overcome these challenges. Presentations will be aimed at a lay audience, in particular school children who will engage in ethics debate. Intended to raise public awareness of the scientific contribution to transplantation and increase interest in the organ donor registry. |
Year(s) Of Engagement Activity | 2010 |
Description | GMEC Genetics Workshop |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Primary Audience | Participants in your research and patient groups |
Results and Impact | The workshop brought together a group of experts and potential collaborators who expressed interest in trying to understand how genetic variation influences the results of transplantation and how this can help to personalise anti-rejection therapy and improve outcomes. The workshop increased awareness of the need for collaboration between UK centres in achieving the goals. It has also resulted in a newsletter on the GMEC and KCL websites, which raised the profile of the necessary work. The presence of a Nature editor at the meeting also raised the possibility of future dissemination. |
Year(s) Of Engagement Activity | 2009 |
Description | Genomic subpopulations and health systems responses |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | Yes |
Primary Audience | Participants in your research and patient groups |
Results and Impact | A workshop to examine developments in genomic subclassification and the impact this is likely to have on health system responses. Emphasis on how advances in genetic immunotyping may change or challenge organ donation and transplantation practice. Greater involvement and understanding of the Centre's work by academics from allied disciplines.. |
Year(s) Of Engagement Activity | 2010 |
Description | KPA Newsletter - The RituxiCAN-C4 trial |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | Yes |
Primary Audience | Public/other audiences |
Results and Impact | Following the talk to the KPA, Professor Dorling was requested to provide a brief overview of his clinical research for the KPA newsletter which was published in May 2010 This was distributed across all dialysis and transplant sites for all the renal patients to see. |
Year(s) Of Engagement Activity | 2010 |
Description | KPA Open Day - How and why we do research on tolerence in kidney transplant patients |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Primary Audience | Participants in your research and patient groups |
Results and Impact | Dr Maria Hernandez-Fuentes explained to patient groups why we do research in biomarkers in tolerence for kidney transplant patients and what are the outcomes so far. The study was mentioned in the national press when it was published in June and other electronic sources in of general science. The importance was given to the fact that we could be eventually able to identify a small groups of patients that may not need as much immunosuppression as it is used now. |
Year(s) Of Engagement Activity | 2010 |
Description | KPA Open Day - The RituxiCAN-C4 trial |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | Professor Anthony Dorling gave an overview of the problem called chronic rejection - the fact that kidney transplants fail prematurely, and outlined the research ongoing to try and address this problem, focusing on the study he has been running, called 'RituxiCAN-C4' Professor Dorling supplied a brief overview of the trial for the KPA newsletter, which was published at the end of May. |
Year(s) Of Engagement Activity | 2010 |
Description | Kidney Patient's Association Open Day |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | Yes |
Primary Audience | Participants in your research and patient groups |
Results and Impact | Laboratory visit and talk concerning ongoing research. Articles in National KPA Newsletter |
Year(s) Of Engagement Activity | 2009 |
Description | Kidney Patients Association Board Presentation |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | Yes |
Primary Audience | Participants in your research and patient groups |
Results and Impact | Summary of translational research including progress with complement inhibitors and potential therapeutics. Ongoing funding notably £750K contribution to the MRC Centre for Transplantation. |
Year(s) Of Engagement Activity | 2007 |
Description | Kidney Patients Association Open Day |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | On Saturday 28th February the MRC Centre threw open its doors to the local KPA, their family and friends. Visitors were treated to a tour of the labs, where staff demonstrated some of the current research techniques and highlighted some of the new initiatives. It was a great opportunity for those affected by kidney disease to learn about the future direction of their treatment. "It is amazing what [they] are doing" said Mr Ron Brooker, one of the visitors. "I enjoyed meeting the people involved...and what wonderful machines!". The lab staff also appreciated meeting the people who will directly benefit from their work. |
Year(s) Of Engagement Activity | 2009 |
Description | Kidney Patients' Association Open Day |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | Yes |
Primary Audience | Participants in your research and patient groups |
Results and Impact | Laboratory visit and talk concerning ongoing research. Articles in National KPA newsletter. |
Year(s) Of Engagement Activity | 2009 |
Description | NICE expert panel |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | National |
Primary Audience | Health professionals |
Results and Impact | LUTS and incontinence guidelines. The role of Role of Botulinum Toxin-A was presented to NICE for due consideration |
Year(s) Of Engagement Activity | 2012 |
Description | PEOPLE Magazine |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | Yes |
Primary Audience | Public/other audiences |
Results and Impact | Article entitled: "Improving transplant sucess". Exposure of the MRC Centre and its work to wides community and Health professionals within the Trust. |
Year(s) Of Engagement Activity | 2009 |
Description | Patient Involvement talks- KPA |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Primary Audience | Public/other audiences |
Results and Impact | Monthly meetings between research staff and kidney patients to explain the research that is taking place in the Centre. Greater patient involvement and understanding of the Centre's work. |
Year(s) Of Engagement Activity | 2010 |
Description | Session Organiser for BSI 2013 |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | Yes |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | National |
Primary Audience | Other academic audiences (collaborators, peers etc.) |
Results and Impact | None as yet - Meeting occurring 2-5 December 2013 |
Year(s) Of Engagement Activity | 2013 |
URL | http://www.bsicongress.com/ |
Description | Social Mobility Foundation Inernship programme |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | Yes |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | The Social Mobility Foundation is organising Internship Programmes every year and the MRC Centre offered to be involved, quote from one of our interns "I just wanted to say a quick thank you as the internship was very useful as it has undoubtedly heightened my understanding of the career path that I am considering. Not only has it allowed me to expand my knowledge beyond the curriculum but it has also boosted my confidence and interpersonal skills. Thank you very much for such a great opportunity." This student is about to start her final year and pass her A levels and move on to a science higher degree. |
Year(s) Of Engagement Activity | 2010,2011,2012,2013,2014 |
URL | http://www.socialmobility.org.uk/ |
Description | TIME magazine |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | No |
Primary Audience | Public/other audiences |
Results and Impact | Prof Steven Sacks was interviewd by TIME magazine and his views were incorporated into the article "In Spain, a transplant that rules out rejection" by Claudia Castillo (November 2008) The MRC Centre for Transplantation has been presented in a wide range of audience in USA. |
Year(s) Of Engagement Activity | 2008 |
Description | The ethics of organ retrieval: goals, rights and responsibilities |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | This was a unique forum bringing together clinicians, academic lawyers, ethicists, policy makers, key stakeholders and members of the public, concerned with organ donation and transplantation. The discussion focused on ethical issues regarding organ retrieval and its impact on transplant services and outcome. Informed policy development on: a. required referral for brainstem death testing and organ donation on the basis of clinical triggers'; b. Donor organ optimisation. Led to a special issue of the Journal Clinical Ethics ""The ethics of organ retrieval' which will examine empirical ethics, law and public policy. |
Year(s) Of Engagement Activity | 2010 |